APL as a second tumor: treatment results according to type of therapy
| Treatment . | No. of patients . | Complete remission, no. (%) . | Induction death, no. (%) . | Resistant disease, no. (%) . |
|---|---|---|---|---|
| AIDA | 31 | 30 (97) | 1 (3) | — |
| ATRA | 8 | 5 (62) | 2 (25) | 1 (12) |
| Other4-150 | 12 | 8 (67) | 4 (33) | — |
| Total | 51 | 43 (84) | 7 (14) | 1 (2) |
| Treatment . | No. of patients . | Complete remission, no. (%) . | Induction death, no. (%) . | Resistant disease, no. (%) . |
|---|---|---|---|---|
| AIDA | 31 | 30 (97) | 1 (3) | — |
| ATRA | 8 | 5 (62) | 2 (25) | 1 (12) |
| Other4-150 | 12 | 8 (67) | 4 (33) | — |
| Total | 51 | 43 (84) | 7 (14) | 1 (2) |
Other treatments include anthracycline or anthracenedione with or without cytosine-arabinoside with or without ATRA.